Halozyme Therapeutics, Inc., a leader in converting IV biologics to subcutaneous delivery, announced the pricing of US$700 million aggregate principal amount of its .25% convertible senior notes due 2027. The convertible notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The Company granted an option to the initial purchasers to purchase up to an additional US$105 million aggregate principal amount of convertible notes.

Latham & Watkins LLP represented the underwriters in the offering with a capital markets deal team led by New York partner Greg Rodgers, San Diego partner Michael Sullivan and with associates Jacob Steele, Andrew Blumenthal, Nicholas Reist, and Ty Balzer.